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ARTICLE
Cryo-EM structures of the XPF-ERCC1
endonuclease reveal how DNA-junction
engagement disrupts an auto-inhibited
conformation
Morgan Jones 1, Fabienne Beuron2, Aaron Borg3, Andrea Nans 4, Christopher P. Earl 1, David C. Briggs 1,
Ambrosius P. Snijders 3, Maureen Bowles1, Edward P. Morris 2, Mark Linch5 & Neil Q. McDonald 1,6✉
The structure-speciﬁc endonuclease XPF-ERCC1 participates in multiple DNA damage repair
pathways including nucleotide excision repair (NER) and inter-strand crosslink repair (ICLR).
How XPF-ERCC1 is catalytically activated by DNA junction substrates is not currently
understood. Here we report cryo-electron microscopy structures of both DNA-free and DNA-
bound human XPF-ERCC1. DNA-free XPF-ERCC1 adopts an auto-inhibited conformation in
which the XPF helical domain masks the ERCC1 (HhH)2 domain and restricts access to the
XPF catalytic site. DNA junction engagement releases the ERCC1 (HhH)2 domain to couple
with the XPF-ERCC1 nuclease/nuclease-like domains. Structure-function data indicate xer-
oderma pigmentosum patient mutations frequently compromise the structural integrity of
XPF-ERCC1. Fanconi anaemia patient mutations in XPF often display substantial in-vitro
activity but are resistant to activation by ICLR recruitment factor SLX4. Our data provide
insights into XPF-ERCC1 architecture and catalytic activation.
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Structure-speciﬁc endonucleases (SSEs) are found in allbranches of life and play crucial roles in genome repair,replication and recombination1. These endonucleases act on
similar DNA structures with deﬁned polarity but use different cat-
alytic mechanisms. The structurally related XPF/MUS81 family are
an important group of human 3′-nucleases that associate to form
two active endonuclease heterodimers (XPF–ERCC1 and MUS81–
EME1) and a DNA translocase (FANCM–FAAP24) with a pseudo-
nuclease architecture2. XPF–ERCC1 recognises double-stranded/
single-stranded (ds/ss) DNA junctions which have a 3′-ssDNA
overhang, nicking the dsDNA backbone to produce a substrate for
subsequent steps in DNA repair pathways. XPF–ERCC1 activity is
essential for removing helical DNA distortions arising from
ultraviolet-induced damage and bulky adducts as part of the
nucleotide excision repair (NER) pathway3. In this context
XPF–ERCC1 nicks the damaged DNA strand 5′ of the lesion at
the ds/ss junction of an NER repair bubble. It is also required for
interstrand cross-link repair (ICLR), some double‐stranded break
repair processes, base excision repair, Holliday junction resolution,
gene-conversion and telomere maintenance4–10. Mutations in XPF
and ERCC1 genes are associated with genetic disorders exhibiting
diverse phenotypes. These pathologies are caused by defects in the
genome maintenance pathways that involve XPF–ERCC1,
including xeroderma pigmentosum (XP), Cockayne’s syndrome,
Fanconi anaemia (FA), XPFE progeria and cerebro-oculo-facio-
skeletal syndrome11–15. The genotype–phenotype correlations of
XPF–ERCC1 driven diseases are still poorly understood.
XPF is the enzymatically active subunit of the heterodimeric
XPF–ERCC1 endonuclease and is comprised of a helicase-like
module (HLM) and a catalytic module (CM) (Fig. 1a). The XPF
HLM is related to the superfamily 2 helicases, with two divergent
RecA-like domains that ﬂank an all α-helical domain16 (Fig. 1a).
Both XPF RecA-like domains, termed RecA-like domain 1
(RecA1) and RecA-like domain 2 (RecA2) lack the residues
necessary to bind and hydrolyse ATP17,18. Despite this, the HLM
is required for full XPF activity and binds both the ICLR
recruitment factor SLX4 and ds/ssDNA structures19,20. The XPF
CM consists of a nuclease domain containing a metal-dependent
GDXnERKX3D active site motif and a tandem helix–hairpin–
helix, termed an (HhH)2 domain21. The smaller ERCC1 subunit
has no catalytic activity but is structurally related to the XPF CM,
consisting of a nuclease-like domain (NLD) and a dsDNA-
binding (HhH)2 domain. Both ERCC1 domains heterodimerise
with their equivalent domains in the XPF CM, forming discrete
nuclease–NLD and 2×(HhH)2 functional units. As well as con-
tributing to XPF stability, ERCC1 can recognise ds/ssDNA sub-
strates and engages the XPA repair protein that is required for
XPF–ERCC1 recruitment to sites of NER22. Currently, there are
no available structures of the XPF HLM or of any full-length
XPF–Mus81 family members. By solving the structure of a near
full-length human XPF–ERCC1 we have deﬁned its overall
architecture and uncovered a previously unreported auto-
regulatory mechanism. We show XPF–ERCC1 adopts an auto-
inhibited conformer in the absence of DNA in order to prevent
promiscuous cleavage and provide structural evidence for the
initial steps of XPF–ERCC1 activation upon binding a DNA
junction.
Results
Structure determination of human XPF–ERCC1 endonuclease.
A single particle cryo-electron microscopy (cryo-EM) density
map of puriﬁed recombinant XPF–ERCC1 complex (128 kDa)
(Fig. 1b) was determined at a global resolution of 4.0 Å (Sup-
plementary Fig. 3a, c, f and Supplementary Movie 1) enabling the
assignment of XPF–ERCC1 domain organisation (Fig. 1c, d). The
map represents the single dominant conformer observed follow-
ing 3D classiﬁcation protocols (Supplementary Fig. 2) and exhi-
bits clear secondary structure features throughout (Fig. 1c and
Supplementary Movie 2). Local resolution analysis (Supplemen-
tary Fig. 3a) indicated that the heterodimeric 2×(HhH)2 domain
exhibited some mobility, so signal subtraction of this domain was
carried out followed by local reﬁnement. This process improved
the global resolution of the resulting sub-volume to 3.6 Å (Sup-
plementary Fig. 3a, d, g) which enabled building, reﬁnement and
validation of an atomic model (Fig. 1d). The locally reﬁned map
shows clear sidechain density throughout with the local resolu-
tion ranging from 3.4 Å in the RecA1 and RecA2 domain cores
(Fig. 1e, f) to 7 Å at the periphery of the ERCC1 NLD. Regions
modelled as polyalanine or omitted from the ﬁnal structure are
shown in Supplementary Table 1. There is no density recovered
for the ERCC1 N-terminus, consistent with it being proteolyti-
cally cleaved (Supplementary Fig. 1b). The N-terminus of ERCC1
is not required for wild-type activity in vitro (Supplementary
Fig. 1d). Inspection of the angular distribution of assigned particle
images during reﬁnement, the 3DFSC curves and 3D ﬂexibility
analysis indicate that resolution differences were due to intrinsic
ﬂexibility rather than a lack of contributing particle images
(Supplementary Fig. 3b, e–g).
Overall architecture of human XPF–ERCC1 endonuclease. The
cryo-EM structure of near full-length XPF–ERCC1 reveals a com-
pact conformation with extensive interactions between the XPF
HLM and CM modules (Fig. 1d). Overall, the HLM adopts a “C”-
shape that has dimensions of approximately 70 × 40 × 60Å. The
two RecA-like domains form a rigid platform and lack a nucleotide
cleft characteristic of many ATP-driven helicases. Instead the two
XPF RecA-like domains are linked through the intimate inter-
twining of secondary structural elements that extend beyond their
globular portion (Supplementary Fig. 4d). While RecA1 caps one
edge of the HLM and engages the XPF nuclease domain in the CM,
the helical domain caps the other HLM extremity and engages the
CM and the dsDNA-binding ERCC1 (HhH)2 domain (Figs. 1d and
2a). This arrangement serves to separate and uncouple both func-
tional domains of ERCC1 through its connecting linker. These
interactions conﬁrm the key regulatory role for the HLM by
engaging crucial elements within the XPF CM and ERCC1. Inter-
faces observed in the XPF–ERCC1 structure were largely validated
using cross-linking mass spectrometry (XL-MS) (Fig. 2f, g) (Sup-
plementary Table 2). Cross-links are found predominately between
both the XPF (HhH)2 domain and the ERCC1 NLD, and between
the XPF RecA2 and ERCC1 NLD. In addition, several cross-links
exceeding the distance cut-off are consistent with two principal
vectors of dynamic movement in solution.
Structure of the XPF HLM. The XPF HLM is typical of other
helicase superfamily 2 (SF2) members with a RecA1–helical
domain–RecA2 organisation, but with substantial inserts within
RecA2 (Fig. 1a). In the absence of ATP binding and hydrolysis
motifs or a nucleotide binding cleft, RecA1–RecA2 are linked
together through a predominantly polar interface (2007 Å2). Major
interface contributions are made by secondary structural elements
ß8 and α20 that form a C-terminal extension to RecA1 and RecA2,
respectively, as well as the XPF amino-terminus (Supplementary
Fig. 4d). ß8 extends the smaller RecA2 four parallel ß-stranded
sheet while α20 packs against the larger RecA1 seven-stranded
parallel beta sheet (ß1–ß7). Additional RecA1–RecA2 contacts
centre on a π-ring stacking interaction between RecA1 domain
Y71XPF and RecA2 domain Y564XPF at one interface edge (Sup-
plementary Fig. 4c) and L39XPF and I592XPF on the other edge.
Polar residues make up the remaining contacts with a small cavity.
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No protein expression was observed for a Y71AXPF mutant
(Table 1). The observed structural rigidity of the RecA1–RecA2
unit is structurally homologous to equivalent domains in
nucleosome-bound chromatin remodellers ISW1 and INO8023,24.
XPF RecA2 has two large inserts with unknown functions.
Insert one (residues 345–377) separates the helical and RecA2
domains and insert two (residues 441–550) interrupts the RecA2
fold. There is sufﬁcient density in our map to trace the backbone
of residues 345–362 and 366–377 from insert one projecting away
from the body of the structure. However, no density was recovered
for insert two, in agreement with predictions that this region
is intrinsically disordered in the absence of DNA. Futhermore,
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Fig. 1 Structure of auto-inhibited human XPF–ERCC1 endonuclease. a Domain architecture of XPF–ERCC1 colour coded by domain. XPF: RecA1 (blue),
helical (green), RecA2 (pink), nuclease (gold) and (HhH)2 (dark grey). ERCC1: NLD (orange) and (HhH)2 (light grey). Residue numbering indicates domain
boundaries and dotted arrows indicate dimerisation interfaces. Two insert sequences within RecA2 are shown in white embellishing the RecA domain fold.
Grey lines deﬁne the helicase-like module (HLM) and catalytic module (CM). b SDS-PAGE gel of puriﬁed recombinant XPF–ERCC1 used for cryo-EM
studies. c Two orthogonal views of the composite XPF–ERCC1 cryo-EM map ranging from a global resolution of 3.6–4 Å, coloured by domain according to
panel a. d Final XPF–ERCC1 atomic model coloured by domain according to panel a, displayed within a transparent cryo-EM potential map. The XPF
nuclease–(HhH)2 and ERCC1 NLD–(HhH)2 domain linker is visible at lower map thresholds. e Representative region of the cryo-EM map close to strand
ß-11 and sidechains from the ﬁnal model in pink. f Representative part of the cryo-EM map close to α-helix 20 with sidechains shown from the ﬁnal model
in pink.
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XL-MS data identiﬁed a large number of intra-insert cross-links
within inserts one and two, consistent with these highly basic
regions being ﬂexible (Supplementary Table 2).
The XPF helical domain is an integral part of the HLM and folds
as a ﬁve anti-parallel helical bundle. This domain packs tightly
against RecA2 and is anchored through an interface centred close to
residues Q300XPF/D302XPF and S412XPF/Q419XPF (Supplementary
Fig. 4b). The Q300AXPF mutant signiﬁcantly reduces XPF–ERCC1
expression and increases aggregation (Table 1). Helix α17 (residues
426–440) also contributes to tethering the helical domain to RecA2.
The observed position of the helical domain determines the
orientation and angle of the extended RecA2 C-terminal α20 helix
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(Supplementary Fig. 4d), stabilising the HLM conformation
through interaction between Q226XPF and T614XPF.
The XPF helical domain regulates XPF–ERCC1 activity. The
XPF HLM is coupled to the CM through contacts from RecA1
and the helical domain (Fig. 2a). RecA1 forms a substantial
interface (1684 Å2) with the XPF nuclease domain involving
aromatic and hydrophobic residues from RecA1 α5 and α6 helices
and XPF nuclease domain η4 and α21 helices and ß14 strand
(Fig. 2b). The hydrophobic nature of the contact suggests that
anchoring of the HLM to the XPF nuclease domain through
RecA1 forms a permanent part of the XPF–ERCC1 architecture.
The XPF helical domain forms a contact with the XPF
nuclease domain that sterically prevents the ds/ssDNA substrate
from reaching the XPF active site (Fig. 2c and Supplementary
Movie 3). A key contact within this auto-inhibited conformation
is between sidechains of H275XPF and S730XPF. A H275AXPF,
W274AXPF double mutant, likely to disrupt this contact, displays
a 1.5-fold increase in catalytic efﬁciency relative to the wild type
(Table 2).
A second autoinhibitory interface exists between the XPF
helical domain and the ERCC1 (HhH)2 domain (Fig. 2d, e and
Supplementary Movie 3). This interface is formed through
predominantly polar contacts involving the highly conserved
T248ERCC1, T252ERCC1 residues and both S312XPF and T316XPF.
Previous structural and biochemical data suggest that the ERCC1
(HhH)2 domain binds dsDNA through hairpin residues
S244ERCC1–N246ERCC1 and G276ERCC1–G278ERCC1 mainchain
atoms25,26. These motifs are proximal to T248ERCC1 and
T252ERCC1, and are not accessible in the DNA-free conformation
of XPF25. The S312AXPF mutant displays a 1.5-fold higher
catalytic efﬁciency than the wild type likely due to the disruption
of this autoinhibitory interaction (Table 2). Equally, shortening
the connecting linker between the XPF nuclease and (HhH)2
domain would be predicted to shift the 2×(HhH)2 unit towards
the nuclease domain releasing the DNA-binding residues. Indeed,
a 829–833ΔXPF mutant displayed a modest 1.2-fold increase in
catalytic efﬁciency and a 7.5-fold tighter Km relative to wild type
(Table 2).
Heterodimerisation of XPF and ERCC1 through two inter-
faces. ERCC1 is intimately coupled to the XPF CM through two
obligate dimerisation surfaces at the equivalent domains of each
molecule. The XPF nuclease domain uses a helix–strand–helix
motif (α25–ß19–α26) to heterodimerise with the equivalent sur-
face of the ERCC1 NLD (α3–ß8–α4) forming a kidney-shaped
dimer with an extensive interaction interface (1684 Å2) (Supple-
mentary Fig. 4a). The contact is predominantly hydrophobic and
is ﬂanked by three salt bridges (Supplementary Fig. 4a). This
interface uses equivalent elements to those mediating hetero-
dimerisation of homologous domains from Mus81–Eme1 and
FANCM–FAAP24 complexes27,28. We note that the XPF (HhH)2
domain hetero-dimerises with the ERCC1 (HhH)2 domain
through predominantly hydrophobic contacts close to F851XPF
and F900XPF as previously observed26,29. The (HhH)2 domain
from XPF and ERCC1 are connected to their XPF nuclease
domain/ERCC1 NLD domain through ordered linker sequences.
There is sufﬁcient density in our cryo-EM map to trace the
mainchain atoms for both linkers (Fig. 1d). The ERCC1 linker
makes unexpected interactions with the XPF nuclease domain via
Y215ERCC1 and D221ERCC1 (Fig. 3b). We note that Y215ERCC1
lies adjacent to S786XPF suggesting the FA mutation S786FXPF
would disrupt this contact with ERCC1. Despite the close asso-
ciation of XPF CM and ERCC1 through heterodimerization, their
respective functional domains remain uncoupled and held apart
through the extended conformation of their connecting linkers.
This is important to consider when comparing with the DNA-
bound conformations (see later).
Structural context of XP and FA patient mutations in XPF.
Recruitment of XPF–ERCC1 into either NER or ICLR pathway
complexes is dependent on interaction with partner proteins XPA
or SLX4 at their respective damaged DNA structures (Fig. 3a). A
previous study mapped the XPA-binding site to a cleft within the
ERCC1 NLD (Fig. 3a)30. This interaction is spatially distinct from
the proposed SLX4 site centred within the helical domain at
L230XPF19. Insights from disease mutations have shown that
repair pathway recruitment can be disrupted by separation-of-
function (FA) or partial loss-of-function (XP) mutations, however
the structural basis for this is unclear31.
With the availability of a three-dimensional XPF–ERCC1 struc-
ture, it was possible to explore the location and structural
environment of disease-causing mutations and correlate this with
their impact on enzyme stability and catalytic activity. Patient-
derived XP or FA-associated mutations were characterised in vitro
using a previously reported ﬂuorescence incision assay20. Mutations
associated with XP mapped primarily to the XPF RecA2 domain
and its inserts15,32,33. L608XPF, R589XPF and T567XPF are located in
the folded region of the RecA2 domain, with the latter two forming
structurally important intra-domain contacts32 (Fig. 3c). Indeed,
L608PXPF and T567AXPF mutant proteins formed soluble aggre-
gates when expressed recombinantly, as measured by analytical size
Fig. 2 Architecture of the XPF helicase-like module and coupling with the catalytic module. a View of the XPF–ERCC1 structure showing the helicase-like
module (HLM as surface rendering) contacts the XPF nuclease domain (gold ribbon cartoon) at two interfaces (dashed red boxes). Domains are coloured
according to the scheme used in Fig. 1. b, c Close-up view of interaction interfaces overlaid with the composite cryo-EM map. Selected residues are
displayed as sticks and coloured by heteroatom, blue—N, Red—O. b The hydrophobic interaction interface between XPF RecA2 (blue) and XPF nuclease
domain (gold). c Interaction of XPF helical domain residues 273–275 (green) with the XPF nuclease domain (gold). d the XPF–ERCC1 HLM (surface
rendered) contacts with the ERCC1 (HhH)2 domain at a single interface (dashed red box). e Interaction of XPF helical domain helix α13 (green) and the
ERCC1 (HhH)2 domain close to its dsDNA-binding residues (pink). f Two orthogonal views of the XPF–ERCC1 structure with XL-MS distance constraints
overlaid. Distances within the allowed Cα–Cα cut-off distance of 30 Å are displayed in blue, distances greater than this cut-off displayed in red. Blue dotted
line indicates a cluster of allowed distances between the XPF helical and ERCC1 (HhH)2 domains. g Cartoon schematic representing inter-domain cross-
links detected by mass spectrometry. Each black line indicates a single unique cross-link between residues in different domains. Domains within the pink
ellipsoid form the XPF HLM, whereas domains within the XPF CM and ERCC1 are within the pale blue ellipsoid.
Table 1 XPF–ERCC1 mutants that disrupt protein folding.
Protein Mutant Mutation
rationale
Effect on protein expression
XPF L608P XP Soluble aggregates
XPF T567A XP Soluble aggregates
XPF R799W XP No expression
XPF Y71A Structural integrity No expression
ERCC1 T248A Autoinhibition No expression
ERCC1 T252A Autoinhibition No expression
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exclusion chromatography (SEC) and an R589WXPF mutant
exhibited 35-fold reduction in catalytic efﬁciency (Table 2). The
R799WXPF XP mutation failed to express recombinantly and lies on
the periphery of the heterodimeric nuclease–NLD interface with
ERCC1 (Fig. 3b). These data, taken in the context of our structure,
suggest the L608PXPF, T567AXPF, R589WXPF and R799WXPF XP
disease mutants compromise XPF–ERCC1 structural stability
(Table 1). I225XPF is also associated with XP32 and maps onto
the hydrophobic core of the helical domain (Fig. 3d) suggesting it is
also likely to contribute to XPF–ERCC1 structural integrity.
FA patients are proﬁcient in NER but deﬁcient in ICLR,
indicating a likely separation of function19,34. Our structure
indicates the FA point mutations within XPF such as L230RXPF,
C236RXPF and G325EXPF cluster within the XPF helical domain
(Fig. 3d)11. These mutants, when expressed recombinantly, were
found to have a similar level of endonuclease activity to wild-type
XPF–ERCC1 against a stem–loop substrate (Table 2). Previous
studies indicated these FA mutations are unable to engage
SLX419. This would impact both the ability of SLX4 to stimulate
XPF–ERCC1 activity35 as well as recruit XPF–ERCC1 to ICLR
sites in vivo19. We found that XPF–ERCC1 co-expressed with a
truncated form of human SLX4 (XPF–ERCC1–SLX4NTD) indeed
showed a six-fold increase in catalytic efﬁciency (Table 3 and
Supplementary Fig. 9a–e). To conﬁrm whether FA XPF–ERCC1
mutant 323–326ΔXPF had a reduced SLX4 association and/or
a negative impact on activity, we measured the amount of
XPF–ERCC1 endonuclease activity recovered after afﬁnity
puriﬁcation followed by gel ﬁltration. The 323–326ΔXPF FA
mutant showed substantially less endonuclease activity (Supple-
mentary Fig. 9d). The FA mutant L230RXPF lies close to XPF
residues 323–326 and was previously shown to be unable to bind
full-length SLX4, indicating that it forms a key determinant of the
SLX4 binding site19. Our data are consistent with a differential
impact of XPF mutants (loss-of-function) affecting NER from
those XPF mutations (separation-of-function) that impact SLX4-
driven activation and interaction in ICLR36.
XPF–ERCC1 conformational activation on DNA-junction
binding. We hypothesised that the autoinhibitory interactions
formed by the XPF helical domain need to be released following
XPF–ERCC1 DNA-junction engagement, prior to the incision
reaction. To probe the nature of such potential conformational
changes, we assembled a complex of XPF–ERCC1 bound to a
DNA stem–loop model substrate (10-duplex 20-T single-strand
stem–loop) that we previously showed presents a single incision
site to XPF–ERCC120. Using an electrophoretic mobility shift
assay (EMSA) we observed 1:1:1 stoichiometric binding of the
stem–loop DNA to XPF–ERCC1 (Supplementary Fig. 5b, c).
This sample was used for cryo-EM data collection leading to a
single-particle cryo-EM density map at a global resolution of 7.7
Å (Supplementary Fig. 6b). Signal subtraction of the dimeric
2×(HhH)2 domain and DNA density, followed by local reﬁne-
ment, improved the resolution of the resulting sub-volume to
5.9 Å (Supplementary Fig. 6c). The locally reﬁned map shows
evidence of helical features, with the local resolution highest in
the core of the RecA domains (Supplementary Fig. 6a). 3DFSC
(Supplementary Fig. 6e, f and Supplementary Movie 4) analysis
indicates that the map does not suffer heavily from anisotropy
and the lower resolution of the DNA-bound map relative to
the DNA-free is as a result of increased ﬂexibility. Indeed,
XPF–ERCC1 does not engage DNA in vivo unless recruited by
XPA in complex with TFIIH37. It is likely that the DNA-bound
XPF–ERCC1 complex only becomes fully stabilised in the
presence of these additional factors.
The DNA-bound reconstruction enabled the placement of all
XPF–ERCC1 domains using the DNA-free structure as an initial
template (Fig. 4a and Supplementary Movie 5). Aligning the
DNA-bound and DNA-free maps identiﬁed key changes in
the architecture of XPF–ERCC1, the most dramatic being the
disengagement of the 2×(HhH)2 domain from the XPF helical
domain and it’s repositioning adjacent to the XPF nuclease—
ERCC1 NLD dimer, as seen for other XPF/Mus81 family
endonucleases27,28 (Fig. 4e). An additional region of density was
identiﬁed adjacent to the 2×(HhH)2 domain but segmented into a
distinct volume (Fig. 4b). This density was assigned as the duplex
portion of the stem–loop substrate due to the unambiguous
presence of a 19 Å concave major groove and its length measuring
the distance of 10 base pairs (Fig. 4c). In order to correctly
position the 2×(HhH)2 domain with respect to the dsDNA, the
structure of the Aeropyrum pernix XPF homodimer in complex
with dsDNA was ﬁt into the map and used to align the human
2×(HhH)2—dsDNA functional unit (Fig. 4b, c). The ﬁt to density
was then optimised for the human structure using Flex-EM38.
This positions the 2×(HhH)2 domain–dsDNA-binding residues
S244ERCC1–N246ERCC1 and G276ERCC1–G278ERCC1 in close
proximity to the dsDNA minor groove in a homologous fashion
to other family members (Fig. 4e). Furthermore, comparison of
the DNA-free and DNA-bound 2D class averages clearly indicates
a repositioning of the 2×(HhH)2 domain upon substrate
engagement (Fig. 4a).
The remaining domains of XPF–ERCC1 can be ﬁt unambigu-
ously into the density. The RecA1–RecA2 unit remains structu-
rally rigid, with high-resolution features present in 2D class
Table 2 Kinetic data for puriﬁed XPF–ERCC1 mutants.
Protein Mutant Mutation rationale Vmax (fmol min−1) Km (nM) kcat (s−1) kcat/Km (nM−1 min−1)
XPF WT 104.7 ± 2.8 12.1 ± 1.4 20.9 ± 0.66 1.73
XPF L230R FA 65 ± 2.1 8.1 ± 1.1 13.0 ± 3.3 1.60
XPF L236R FA/CS 91.2 ± 2.5 10.8 ± 1.2 18.2 ± 0.5 1.69
XPF E239K FA 88.9 ± 4.7 12.4 ± 2.1 16.9 ± 0.7 1.36
XPF S786F ICLR deﬁcient 80.9 ± 3.8 32.5 ± 1.5 7.9 ± 0.8 0.24
XPF 323–326 Δ ICLR deﬁcient 120.2 ± 1.4 20.5 ± 0.8 24.2 ± 0.3 1.18
XPF S312A Autoinhibition 126.1 ± 28.2 5.1 13.5 ± 1.8 2.65
XPF W274A, H275A Autoinhibition 193.4 ± 8.6 15.2 ± 2.4 38.7 ± 1.3 2.55
XPF R112A DNA binding 24.5 ± 1.1 4.32 ± 0.63 5.6 ± 0.2 1.30
XPF 829–833 Δ Autoinhibition linker disruption 20.2 ± 0.5 1.9 ± 1.2 3.8 ± 0.2 2.00
XPF R589W XP 8.22 ± 2.6 25.9 ± 6.1 1.4 ± 0.9 0.05
ERCC1 L253A Autoinhibition 33.1 ± 2.7 28.7 ± 22.3 3.4 ± 0.3 0.12
Each kinetic value was obtained from 3 technical replicates (n= 3) ± standard deviation (SD).
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Fig. 3 Mapping XPF–ERCC1 disease mutations and DNA repair pathway recruitment sites. a Top, a ribbon model of XPF–ERCC1 highlighting the
spatially distinct binding sites of XPA and SLX4. XPA binds to the ERCC1 NLD (orange) and SLX4 binds to the XPF helical domain (green). The XPA
peptide (residues 66–77) atoms are displayed as red spheres (PDB: 2JNW). The key SLX4 binding residue L230 sidechain atoms are also displayed as
red spheres. Bottom, representative DNA structures targeted by XPF–ERCC1 through SLX4 (interstrand cross-link) or XPA (intrastrand cross-
link) recruitment. b–d The molecular environment of patient-derived disease mutations are indicated on the structure, superposed with the cryo-EM
map displayed close to the mutation site. Selected residues are displayed using stick rendering coloured by heteroatom. Residues associated with
Fanconi anaemia (FA) patient mutations are coloured red whilst those associated with XP are coloured black. Black or orange dashed ellipses indicate
the environment close to XP or FA mutations respectively. bMutations in the XPF nuclease domain and ERCC1 NLD lie close to their interface and give
rise to both FA and XP. c XP-associated mutations disrupt key structural contacts in the XPF RecA2 domain are shown overlaid with the composite
cryo-EM map. d FA-associated mutations cluster within the XPF helical domain. The helical domain also contains the XP-associated mutant,
I225 (black).
Table 3 SLX41–758–XPF–ERCC1 mutation data summary.
Protein Mutant Vmax (fmol min−1) Km (nM) kcat (min−1) kcat/Km (nM−1 min−1)
XPF(–ERCC1–SLX4NTD) WT 219.2 ± 9.3 4.2 ± 0.7 43.8 ± 1.1 10.4
XPF(–ERCC1–SLX4NTD) 323–326 Δ 49 ± 6.5 32.2 ± 9.6 9.8 ± 1.4 0.30
XPF(–ERCC1) WT 104.7 ± 2.8 12.1 ± 1.4 20.9 ± 0.66 1.73
Each kinetic value was obtained from 3 technical replicates (n= 3) ± the standard deviation (SD).
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averages (Fig. 4f, g), reafﬁrming its role as an inactive helicase.
Whilst the remainder of the complex increases in ﬂexibility upon
substrate engagement (Fig. 4g), the interface between the XPF
RecA1 and nuclease domains remains intact (Fig. 4d). Compar-
ison with the DNA-free structure reveals that the XPF helical
domain pivots by approximately 15°, rotating ~11 Å away from
the nuclease domain (Supplementary Fig. 7a). The increased
ﬂexibility of the XPF helical domain following its disengagement
with the XPF nuclease domain can be visualised by the loss of
high-resolution features in 2D class averages following substrate
engagement (Fig. 4g). This conformational change breaks the
autoinhibitory contact formed between H275XPF and S730XPF as
predicted from the DNA-free structure. The remaining unmo-
deled map density likely corresponds to the ﬂexible ﬁrst RecA2
domain insert (Fig. 4b).
A model for DNA junction-based activation. Tight regulation of
endonuclease catalytic activity is needed to prevent inappropriate
DNA cleavage. Indeed XPF–ERCC1 displays no activity towards
DNA duplexes, ssDNA or an equimolar mixture of ds and ssDNA
substrate (Fig. 5b). This implies that it is the proximity of the
ssDNA and dsDNA elements in a junction context that is
uniquely required to stimulate XPF–ERCC1 activation and
overcome complex autoinhibition. Analysis of our DNA-bound
structure reveals that the presence of a junction shifts the dimeric
2×(HhH)2 domain by 47 Å to contact the XPF nuclease–ERCC1
NLD dimer, disrupting contacts with the XPF helical domain
(Fig. 5a, b, Supplementary Movies 9 and 10). In this conﬁguration
the dimeric 2×(HhH)2 domain lies proximal to the ERCC1 NLD
domain, coupling both known ssDNA-binding elements of the
endonuclease25,27,28,39 within the ERCC1 NLD and XPF (HhH)2
domain (Fig. 5a, b). Others have proposed that XPF–ERCC1
2×(HhH)2 domain is sufﬁcient to recognise ds/ssDNA junc-
tions40, however, the precise arrangement of multiple ssDNA and
dsDNA domains required for DNA-junction recognition remains
to be determined. The ﬁnal DNA-bound model lacks the single-
stranded portion of the stem–loop and places the scissile phos-
phodiester bond approximately 15 Å from the XPF active site
motif (residues 725–727) (Fig. 5b). We interpret the DNA-bound
structure as showing important features of an initial step towards
full DNA-junction recognition prior to the incision reaction. The
low resolution of the DNA component within the cryo-EM map
(approximately 9 Å) suggests that the dimeric 2×(HhH)2–DNA
complex can adopt multiple conformers. Equally, the accessibility
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of the dsDNA major groove opposite to the 2×(HhH)2 minor
groove interaction could be re-oriented towards the positively
charged concave surface within the XPF HLM (Fig. 5c, d).
The closest structural homologue of both DNA-bound and
DNA-free structures, as identiﬁed by the DALI protein structural
comparison server41, is the helicase/translocase MDA5 that binds
dsRNA40–42 (rmsd of 4.1 Å over 283 C-alphas) (Fig. 5d and
Supplementary Fig. 7b, c). MDA5 binds to the major groove of A-
form dsRNA using a concave surface lined with basic residues
and sequences equivalent to the XPF RecA2 insert two spanning
residues 441–550 (Fig. 5d). A similar positively charged concave
surface is evident for XPF HLM. Additional density is apparent
adjacent to the RecA2 ß-sheet and could represent part of the
missing insert two (disordered in the DNA-free structure), and is
analogous to a dsRNA-binding region of MDA5. In the absence
of DNA, the concave surface of the auto-inhibited conformation
of the XPF HLM is too narrow to accommodate dsDNA,
however. Upon release of the autoinhibitory contact between the
XPF helical and nuclease domains following substrate engage-
ment the HLM opens up into a conformation more conducive to
dsDNA major groove binding. Further experiments using
substrates with longer dsDNA regions or with A-/B-form DNA
duplexes are required in order to validate this proposed mode of
binding (Supplementary Fig. 8c).
Superposition of an XPF (HhH)2 domain bound to ssDNA
(PDB: 2KN7) with our DNA-free structure reveals that the
distance between the ssDNA-binding sites on the XPF (HhH)2
domain and the ERCC1 NLD is too far (>50 Å) to be engaged
simultaneously by the 20-thymine residue stem–loop (Fig. 5a).
Movement of the 2×(HhH)2 domain in the presence of a
stem–loop shortens this distance to approximately 30 Å (Fig. 5b)
This is consistent with changes in (HhH)2 domain position and
linkers observed in published structures for A. pernix XPF and
Mus81–Eme1 in the presence and absence DNA. It is also
supported by both our 3D variability analysis (Supplementary
Movies 6–8) and by XLMS data. We therefore speculate that
longer junction substrates may reveal even further dynamic
rearrangements sufﬁcient to place a junction at the nuclease
active site (Fig. 5e).
Discussion
The structural and functional studies described in this report
provide insights into XPF–ERCC1 architecture, regulation and
activation. The XPF–ERCC1 endonuclease catalyses the ﬁrst
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irreversible step in NER repair by nicking the 5′-edge of the repair
bubble structure on the damaged strand. The structure of DNA-
free XPF–ERCC1 reveals how the heterodimer is auto-inhibited
by blocking both DNA binding and active site access through
contacts with the XPF helical domain. This structure reveals
inter-domain interfaces not previously described and rationalises
our previous report that the HLM impacts on endonuclease
activity and substrate interaction20. Whilst the ssDNA-binding
surfaces of XPF (HhH)2 and ERCC1–NLD are fully solvent
accessible in the auto-inhibited structure, they are uncoupled
from their respective dsDNA-binding surfaces (ERCC1 (HhH)2
and XPF–HLM), which are sterically blocked. The structure also
conﬁrms the presence of a heterodimeric interface between the
XPF nuclease and ERCC1 NLD as described for other family
members25,27,28.
This study provides evidence linking conformational activation
of XPF–ERCC1 through DNA-junction recognition, with a likely
contribution from recruitment partner proteins at DNA-junction
sites prepared for either NER or ICLR pathways. Mapping the
XPA interaction site within ERCC130 and the SLX4 site within
XPF helical domain reveals spatial separation of each recruitment
partner site in the auto-inhibited state. It suggests the critical
binding determinants are non-overlapping, but full structures of
XPF–ERCC1 with SLX4 or XPA combined with competition
binding studies are required to prove this. XPF–ERCC1 activation
by SLX4 is disrupted by some FA mutations that map to the
helical domain, in agreement with previous in vivo work19,34.
Given its proposed regulatory role, the helical domain may be
repositioned on binding SLX4 to stimulate activity35,43. In con-
trast, XP-associated mutations were found to generally reduce
endonuclease activity in vitro towards an NER substrate by
destabilising the complex whereas FA mutants exhibited activity
similar to wild type. Interestingly, our XPF–ERCC1 preparations
were found to contain a signiﬁcant amount of active XPF–ERCC1
heterotetramer (Supplementary Fig. 1a, c, d). Cryo-EM data was
collected for this sample, although it was not possible to obtain a
reconstruction below 14 Å resolution due to intrinsic ﬂexibility
(Supplementary Fig. 1e, f). Despite this, future work will seek to
address whether the XPF–ERCC1 heterodimer and hetero-
tetramer play distinct roles in DNA repair pathways.
XPF–ERCC1 cryo-EM structures described here reveal how
binding a DNA-junction substrate is able to disengage the XPF
helical domain from the XPF CM and release the heterodimeric
2×(HhH)2 domain. A role for the linker regions in enabling this
release is likely. The released 2×(HhH)2 domain is then able to
engage a minor groove in a dsDNA duplex adjacent to the DNA
ds/ss junction and packs against the XPF nuclease–ERCC1 NLD
dimer, as observed for structures of Mus81–Eme1 and A. pernix
XPF. The repositioning of the dimeric 2×(HhH)2 domain has
three consequences. First, it destabilises the autoinhibition inter-
face with the XPF helical domain. Second, it exposes the dsDNA-
binding surface of ERCC1 (HhH)2. Third, it enables the proper
coupling of the ERCC1 ssDNA and dsDNA-binding functions by
shortening the linker regions and forming a compact conforma-
tion with ERCC1–NLD–(HhH)2 domain contacts. The structures
described here do not reveal the full basis for DNA-junction
recognition or the extent of conformational ﬂexing required to
place the scissile bond proximal to the XPF catalytic centre. We
speculate that the similarities between XPF HLM and the MDA5
helicase point to a concave surface that could engage the major
groove of a DNA duplex within a DNA junction to promote
movement of the ds-ssDNA discontinuity into the XPF catalytic
site. Evidently further high-resolution structures are required with
longer DNA substrates and recruitment partner complexes in
order to fully understand how the scissile phosphodiester bond is
presented to the XPF catalytic site and the extent of the con-
formational alterations required.
Whilst this paper was in preparation, the structure of a ds/
ssDNA-bound TFIIH–XPA (PDB code: 6RO4) was published
representing a 5′-NER pre-incision complex that can recruit
XPF–ERCC137. Superposition of the ERCC1 (HhH)2 domain–
dsDNA complex onto the exposed DNA minor groove at the
TFIIH–XPA–ds-ssDNA junction (Supplementary Fig. 8b) revealed
a non-overlapping complementarity in DNA binding with XPA.
ERCC1 engaged precisely the available DNA elements that were
not engaged by XPA (Supplementary Fig. 8a). The resulting mod-
el predicts extensive interfaces between the XPF–ERCC1 and
TFIIH–XPA–DNA with few steric clashes, many of which were
within the ﬂexible XPA loop region (residues 104–131). In this
model, the dimeric 2×(HhH)2 domain lies adjacent to the TFIIH
subunit XPB and DNA whilst the XPF nuclease–ERCC1 NLD
dimer is positioned close to XPD, XPA and DNA. The highly basic
and ﬂexible RecA2 insert one (residues 345–377) is oriented to
interact with either the extended XPA helix or dsDNA. Further
structural studies are required to validate such a model.
Finally, there is a pressing need to explore chemical inhibition
of XPF–ERCC1 to sensitise cancer cells to platinum-based
therapeutics and reduce drug resistance mediated by XPF-
ERCC1. Equally, XPF-ERCC1 inhibitors could target cancer cell
vulnerabilities including XPF-FANCM synthetic lethality relevant
to FANCM-deﬁcient tumours44 and potentially other platinum-
sensitive contexts45. The availability of an atomic structure for
human XPF–ERCC1 described here will encourage efforts to
develop new precision medicines as well as to overcome cancer
chemoresistance46.
Methods
XPF–ERCC1 expression, puriﬁcation and complex assembly. All reagents pur-
chased from Sigma-Aldrich unless otherwise stated. A pFastBac Dual vector con-
taining full length, wild type, human XPF (NCBI reference sequence:
NM_005236.2) and ERCC1 (NCBI reference sequence: NM_001166049.2) cDNA
was modiﬁed to include a C-terminal ERCC1 Twin-Strep-tag using restriction
enzyme cloning. All primer sequences used in this study are shown in Supple-
mentary Table 3. This plasmid was transformed into competent DH10BAC
Escherichia coli cells (Thermo-Fisher) and recombinant bacmid DNA puriﬁed.
Recombinant baculoviruses expressing XPF and ERCC1 were generated using
standard protocols47 (Oxford Expression Technologies). In short, 1 × 106 SF21 cells
(Thermo-Fisher) grown in SFIII media (Thermo-Fisher) and 10 μg/ml gentamycin
(Life Technologies) were infected at a multiplicity of infection (MOI) of 2 and
harvested after 72 h. Cell pellets were resuspended in extract buffer (20 mM HEPES
pH 7.8, 150 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine (TCEP), 10% glycerol,
2 mM MgCl2, 0.01% 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfo-
nate (CHAPS), 0.25 tablet of EDTA-free protease-inhibitor cocktail per litre of
culture, and 1 μl per 250 mL lysate BaseMuncher (Expedeon)) and lysed by soni-
cation. The lysate was cleared of insoluble cell debris by centrifugation at 35,000g
for 45 min and incubated with Strep-tactin resin (GE Healthcare) for 1 h at 4 °C.
The resin was extensively washed with extract buffer minus protease inhibitors and
BaseMuncher and incubated for 12 hours with Tobacco Etch Virus protease
(supplier NEB). The eluate, containing XPF–ERCC1 was concentrated and loaded
onto an anion-exchange column (HiTrap-Q, GE Healthcare) and XPF–ERCC1
containing fractions eluted using a gradient across 20 ml of extract buffer+ 1M
NaCl before a ﬁnal SEC step using a Superdex-200i column (GE Healthcare) in
cryo buffer (20 mM HEPES pH 7.8, 150 mM NaCl, 1 mM TCEP, 0.01% CHAPS).
Mutants were cloned using the Q5 site-directed mutagenesis kit (New-England
Biotech) and were then expressed using the same protocol as described above for
wild-type XPF–ERCC1.
XPF–ERCC1 DNA complex assembly. DNA with a modiﬁed phosphorothioate
backbone (SLp DNA) was resuspended in DNA resuspension buffer (10 mM Tris,
pH 7.8, 1 mM EDTA and 75mM NaCl) and annealed to form a stem–loop
structure. Puriﬁed XPF–ERCC1 was buffer exchanged into XPF–ERCC1 DNA cryo
buffer (20 mM HEPES pH 7.8, 150 mM NaCl, 1 mM TCEP, 0.01% CHAPS, 5 mM
CaCl2, 0.5 mM EDTA) and then incubated with SLp DNA at a 1:2 protein:DNA
molar ratio for 10 min at 4 °C followed by cross-linking with 0.05% (v/v) glutar-
aldehyde for 10 min at 4 °C. The cross-linking reaction was quenched by the
addition of 1 mM Tris-HCl, pH 7.8 and the complex further puriﬁed via SEC using
a Superdex 200i column.
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Stem–loop sequence:
CAGCG*C*T*U*G*G*TTTTTTTTTTTTTTTTTTTT*C*C*A*A*G*CGCTG,
where the asterisk * represents a phosphorothioate backbone.
XPF–ERCC1 cryo-EM grid preparation and data collection. For cryo-EM ana-
lysis, 4 μl of the puriﬁed XPF–ERCC1 heterodimer at 1.5 mg/ml was applied to
both R1.2/1.3 400 mesh UltraFoil® and QuantiFoil® grids that had been previously
glow discharged for 45 s at 42 mA. The grids were blotted for 4 s at 100% humidity
and 4 °C and plunged into liquid ethane cooled by liquid nitrogen using a FEI
Vitrobot MK IV. The grids were then loaded onto a Titan Krios transmission
electron microscope operated at 300 kV (Thermo-Fisher). Images were collected in
counting mode using a Gatan K2 Summit direct electron detector camera mounted
behind a GIF Quantum energy ﬁlter operating in zero-loss mode. Exposures were
15 s, with a total dose of 63 e−/Å2 dose-fractionated into 40 frames with a cali-
brated pixel size of 1.38 Å. Images were recorded with a defocus of 1.5 µm to 4 µm.
A total of 15,315 micrographs were collected from three separate data collection
sessions.
XPF–ERCC1 cryo-EM image processing. Movie frames were corrected for motion
using MotionCor248, and contrast transfer function was estimated using
CTFﬁnd4.149 within Scipion1.250. The total number of movies used for processing
was 14,453. Two-hundred micrographs were selected from the ﬁrst collection from
which 82,412 particles were picked using Xmipp351 semi-automated picking and
extracted using RELION-352. The particles were sorted using Xmipp351 screen
particles followed by three rounds of reference-free 2D classiﬁcation in
CryoSPARC-253. A subset of six 2D classes were selected that represented different
views of the molecule and used as templates for reference-based particle picking
using Gautomatch54 on the full dataset. This approach yielded 396,106, 1,201,881
and 2,391,900 particles for data collection runs one, two and three, respectively.
The particles were extracted and binned twofold using RELION-352, sorted using
Xmipp351 to screen particles and then submitted for three rounds of reference-free
2D classiﬁcation in CryoSPARC-253. This reduced the particle numbers to 151,412,
390,007 and 1,074,111 particles for data collection runs one, two and three,
respectively. Four initial models were generated using the ab initio reconstruction
programme in CryoSPARC-253 and were used as references for 3D classiﬁcation
using heterogeneous reﬁnement in CryoSPARC-253. Multiple rounds of hetero-
geneous reﬁnement yielded 44,312, 126,492 and 390,712 particles in well-deﬁned
classes for data collection runs one, two and three respectively. All 561,516 particles
from the three collections were re-extracted in an un-binned 200 ×200 pixel box
using RELION-352 and csparc2star and then merged. The data then underwent 3D
classiﬁcation without alignment in RELION-352 to identify the most stable, high-
resolution class. The two classes that displayed the highest-resolution features,
comprising 405,339 particles, were reﬁned to 4.1 Å resolution in CryoSPARC-253
using non-uniform reﬁnement. Per-particle motion correction was carried out
using Bayesian polishing in RELION-352. The shiny, polished particles were then
reﬁned to 4.0 Å resolution in CryoSPARC-253 using non-uniform reﬁnement.
Inspection of the 4.0 Å resolution map rendered by local resolution in
Chimera55 identiﬁed the dimeric XPF–ERCC1 2×(HhH)2 domain as the lowest
resolution region of the map, suggesting some degree of mobility. A mask which
excluded the low-resolution XPF–ERCC1 2×(HhH)2 hairpins was generated in
Chimera55 and using the particle subtraction tool in CryoSPARC-253 the portion of
the particle images aligning to the hairpin density in the map was removed. Non-
uniform local reﬁnement in CryoSPARC-253 was performed on the subtracted
particles, re-aligning them to the masked reference volume, leading to a
reconstruction at 3.6 Å resolution which excluded the hairpin portion of the
4.0 Å map.
All resolutions reported here were determined by Fourier shell correlation (at
FSC= 0.143) based on the “gold-standard” protocol using a soft mask around the
complex density56. To avoid over-masking, the masked maps were visually
inspected to exclude the possibility of clipping. In addition, the occurrence of over-
masking was monitored by inspecting the shapes of FSC curves. The two-half maps
had their phases randomised beyond the resolution at which the no-mask FSC
drops below the FSC= 0.143 criterion. The tight mask is applied to both half maps,
and an FSC is calculated. This FSC is used along with the original FSC before phase
randomisation to compute the corrected FSC. Local resolution was calculated using
Blocres within CryoSPARC-253. For visualisation, maps were sharpened by
applying an automated local resolution weighted negative B factor using the local
ﬁltering function of CryoSPARC-253.
XPF–ERCC1 model building. Initially the crystal structures of the ERCC1 NLD
(PDB code: 2A1I) and the tandem helix–hairpin–helix domains comprising XPF
and ERCC1 chains (PDB code: 2A1J) were rigid body ﬁtted into the locally ﬁltered
and sharpened map obtained at 4.0 Å resolution. Homology models were generated
for the XPF RecA1 domain and rigid body ﬁt into the map using the same pro-
cedure. Subsequently, the ﬁtted domains were rebuilt manually using COOT57
optimising the ﬁt where sidechain densities were evident prior to using FlexEM38
and real-space reﬁnement as implemented in PHENIX58 whilst imposing sec-
ondary structural and geometric restraints to prevent overﬁtting (Table 4).
The RecA2 and helical domains were built de novo and subjected to PHENIX58
real-space reﬁnement. A further 6 cycles of rebuilding and reﬁnement in COOT57
and PHENIX58 lead to a model containing 743 residues from XPF and 195 from
ERCC1. Linkers regions connecting the XPF nuclease and ERCC1 NLD domains to
their respective (HhH)2 domains were built manually into the map and the N-
terminal portion of the XPF nuclease domain homology model was rebuilt in
COOT57 to ﬁt the map. The ﬁnal atomic model was evaluated using MolProbity59
(Table 4). The location of patient mutations and sidechains referred to in the text
are mapped onto the primary sequence, together with sequence conservation
within XPF and ERCC1 homologues respectively (Supplementary Figs. 10 and 11).
XPF–ERCC1–DNA complex cryo-EM grids and data collection.
XPF–ERCC1–DNA complex was concentrated to 1.3 mg/ml and applied to
Quantifoil R1.2/1.3 300 mesh copper grids. The freezing and imaging conditions
used were the same as for the DNA-free XPF–ERCC1 complex described above. A
total of 8965 movies were collected from a single data collection using the same
electron microscope and detector as described above.
XPF–ERCC1–DNA complex cryo-EM image processing. Motion correction and
CTF estimation was performed as previously described for the XPF–ERCC1 data
collections. Totally, 7982 micrographs were manually selected for processing.
Particle picking was carried out as described for the XPF–ERCC1 data collections.
3,432,565 particles were extracted and sorted using Xmipp351 screen particles and
then submitted for six rounds of reference-free 2D classiﬁcation in CryoSPARC-
253. A total of 688,821 particles were used to generate 4 ab initio reconstructions
which were then used as references for 3D classiﬁcation using heterogeneous
reﬁnement in CryoSPARC-253. Multiple rounds of heterogeneous reﬁnement were
carried out yielding one well-ordered reconstruction comprising 199,022 particle
images (Table 4). This class was reﬁned to 7.7 Å resolution using non-uniform
reﬁnement in CryoSPARC-253. A mask was generated using UCSF Chimera55 that
Table 4 Cryo-EM statistics for XPF–ERCC1 structures and
associated maps.
Data Collection and
Processing
XPF–ERCC1 XPF–ERCC1DNA
EMDB ID EMD-10337 EMD-10338
PDB ID 6SXA 6SXB
Magniﬁcation 36,232× 36,232×
Voltage (kV) 300 300
Electron exposure (e−/Å2) 63 63
Defocus range (μm) 1–4 1–3
Pixel size (Å) 1.38 1.38
Symmetry imposed C1 C1
Initial particle images 3,989,887 3,432,565
Final particle images 405,339 199,022
Map resolution (Å) 3.6 (local
reﬁnement)
7.9 (globally reﬁned)
4.0 (globally
reﬁned)
7.1 (local reﬁnement)
Map resolution range (Å) 3.4–8 5.5–14
Reﬁnement
Initial model Cryo-SPARC
ab initio
Cryo-SPARC ab initio
Model resolution (Å) 3.6–4 5.9–7.7
FSC threshold 0.5 0.5
Map sharpening B
factor (Å2)
−168 −560
Model composition
Non-hydrogen atoms 7218 7345
Protein residues 945 892
B factor (Å2) 163 530
R.m.s. deviations
Bond lengths (Å) 0.004 0.23
Bond angles (°) 0.682 0.37
Validation
MolProbity score 1.88 2.9
Clashscore 7.01 4
Poor rotamers (%) 0 0
Ramachandran plot
Favoured (%) 91.7 99
Allowed (%) 8.4 1
Disallowed (%) 0 0
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excluded both the DNA and hairpin domain density which was used to carry out
masked reﬁnement improving the resolution of the sub-volume to 5.9 Å (Table 4).
XPF–ERCC1–DNA complex model building. Individual domains of XPF–ERCC1
were taken from the DNA-free structure and ﬁtted into the DNA-bound cryo-EM
map density as rigid bodies using the UCSF Chimera55 ﬁt-in-map tool. The
homodimeric A. pernix XPF (PDB:2BGW) bound to dsDNA through its (HhH)2
hairpins was ﬁtted into the DNA-bound map density and the subsequent position
of the DNA-bound A. pernix hairpins used as a reference to align the human
hairpin domain using MatchMaker in UCSF Chimera55. The DNA from the A.
pernix structure was reduced to a 10 base-pair duplex and modelled into the map
whilst preserving the hairpin domain–DNA contacts. The sequence conservation of
the functional human ERCC1 and A. pernix (HhH)2 domains is high: 25.5%
identical and 69.1% similar residues. The ds-RNA bound structure of MDA5 (PDB:
4GL2) was placed into the DNA-bound map density as a guide to place the helical
domain of XPF by inspecting the position of the homologous domain in MDA5.
XPF–ERCC1–DNA–TFIIH–XPA complex modelling. The XPF–ERCC1–DNA
structure was aligned to the TFIIH–DNA–XPA structure (PDB code: 6RO4)
through structural super-imposition in UCSF Chimera55 and alignment with the
two DNA strands of a single duplex from each structure. The ds/ss DNA junction
was deﬁned by the high-resolution DNA structure in the TFIIH–XPA complex and
demarcated by the position of the XPA β-hairpin.
XPF–ERCC1 cross-linking mass spectrometry. All chemicals were purchased
from Sigma-Aldrich unless otherwise stated. A total of 100 µg XPF–ERCC1 het-
erodimer at a concentration of 1 mg/ml in 20 mM HEPES, pH 7.8, 10% Glycerol,
0.01% CHAPS, 150 mM NaCl, 1 mM TCEP, 0.5 mM EDTA was cross-linked using
1 mM disuccinimidyl sulfoxide (DSSO) (Thermo-Fisher) with mild shaking for
30 min at 37 °C. The reaction was quenched using a ﬁnal concentration of 50 mM
ammonium bicarbonate for a further 20 min at 37 °C. To remove potential
aggregates, gradient ultracentrifugation was employed using a 5–30% glycerol
gradient in 20 mM Hepes, 150 mM NaCl, mixed using a Gradient Master (Bio-
Comp), and centrifuged for 16 h at 4 °C at 200,000×g using a SW 55 Ti Rotor
(Beckman Coulter)60. Totally, 100 µL fractions were collected and silver stained to
identify fractions containing cross-linked non-aggregated XPF–ERCC1. Fractions
containing cross-linked proteins were then pooled and buffer exchanged into 8 M
urea using a Vivaspin 500, 30,000 molecular weight cut off (MWCO) PES ﬁlter
(Sartorius, VS0122). Cysteine reduction was carried out using 2.5 mM TCEP for
30 min at 37 °C and alkylated in the dark using 5 mM iodoacetamide at room
temperature. The urea was then buffer exchanged for 50 mM ammonium bicar-
bonate and proteins were proteolysed using trypsin (Promega) at 1:50 w/w trypsin:
protein overnight at 37 °C. The solution was acidiﬁed using 2% formic acid and
peptides were the spun through the MWCO ﬁlter and desalted using in-house built
STAGE tips made using Empore SPE C18 discs (3 M, 66883-U). The eluent was
then dried to completion. Peptides were reconstituted in 0.1% triﬂuoroacetic acid
(TFA) and chromatographically resolved using an Ultimate 3000 RSLCnano
(Dionex) HPLC. Peptides were ﬁrst loaded onto an Acclaim PepMap 100 C18,
3 µm particle size, 100 Å pore size, 20 mm × 75 µm ID (Thermo Scientiﬁc, 164535)
trap column using a loading buffer (2% acetonitrile (MeCN) and 0.05% TFA in
97.05 % H2O) with a ﬂow rate of 7 µL/min. Chromatographic separation was
achieved using an EASY-Spray column, PepMap C18, 2 µm particles, 100 Å pore
size, 500 mm × 75 µm ID (Thermo Scientiﬁc, ES803). The gradient utilised a ﬂow of
0.3 µl/min, starting at 98% mobile A (0.1% formic acid, 5% dimethyl sulfoxide
(DMSO) in H2O) and 2% mobile B (0.1% formic acid, 75% MeCN, 5% DMSO and
19.9% H2O). After 6 min, mobile B was increased to 30% over 69 min, to 45% over
30 min, further increased to 90% in 16 min and held for 4 min. Finally, Mobile B
was reduced back to 5% over 1 min for the rest of the acquisition. Data were
acquired in real time over 140 min using an Orbitrap Fusion Lumos Tribrid mass
spectrometer in positive, top speed mode with a cycle time of 5 s. The chroma-
togram (MS1) was captured using 60,000 resolution, a scan range of 375–1500 with
a 50 ms maximum injection time, and 4e5 AGC target. Dynamic exclusion with
repeat count 2, exclusion duration of 30 s, 20 ppm tolerance window was used,
along with isotope exclusion, a minimum intensity exclusion of 2e4, charge state
inclusion of 3–8 ions and peptide mono isotopic precursor selection. Precursors
within a 1.6 m/z isolation window were then fragmented using 25% normalised
CID, 100 ms maximum injection time and 5e4 AGC target. Scans were recorded
using 30,000 resolution in centroid mode, with a scan range of 120–2000 m/z.
Spectra containing peaks with a mass difference of 31.9721 Da were further frag-
mented with a 30% normalised higher collision induced dissociation, using a 2 m/z
isolation window, 150 ms maximum injection time and 2e4 AGC target. Four scans
were recorded using an ion trap detection in rapid mode starting at 120 m/z.
XL-MS data analysis. Data processing were carried out using Proteome Dis-
coverer Version 2.4 (Thermo Scientiﬁc) with the XlinkX61 node where the mini-
mum XlinkX score was set to 63. The acquisition strategy was set to MS2_MS3
mode. The database comprised solely of the speciﬁc XPF and ERCC1 sequences.
Trypsin was selected as the proteolytic enzyme allowing up to two missed cleavages
with a minimal peptide length of ﬁve residues. Masses considered were in the range
of 300–10000 Da. The precursor mass tolerance, FTMS fragment mass tolerance,
and ITMS Fragment Mass Tolerance were set to 10 ppm, 20 ppm and 0.6 Da,
respectively. A static carbamidomethyl (+57.021 Da) modiﬁcation was utilised for
cysteine residues, with additional dynamic modiﬁcations considered including;
amidated and hydrolysed DSSO (+142.050 and +176.014 Da, respectively) on
lysine serine and threonine residues, oxidation (+15.995 Da) on methionine resi-
dues, and protein N-terminal acetylation (+42.011 Da). The FDR threshold was set
to one with the strategy set to simple. The list of reported cross-linked spectral
matches were manually examined and cross-links with spectra that did not contain
acceptable b and y ion coverage were excluded. We note that this method requires
accessible lysine sidechains therefore predominantly hydrophobic interfaces, such
as the RecA1–nuclease, did not return any cross-links62. A number of cross-links
were observed that exceed the permitted the Cα–Cα cut-off distance of 30 Å.
XPF–ERCC1–SLX4NTD complex assembly. cDNA encoding the SLX4NTD (resi-
dues 1–758) (NCBI reference sequence: NM_032444) was shuttled into a pGEX-1
vector (Sigma). Recombinant baculoviruses expressing the SLX4NTD were gener-
ated as previously described and used to infect 1 × 106 SF21 cells (Thermo-Fisher)
grown in SFIII media (Thermo-Fisher) and 10 μg/ml gentamycin (Life Technolo-
gies) at an MOI of 0.5. These cells were co-infected with XPF–ERCC1 expressing
baculovirus at an MOI of 2. Cells were pelleted after 72 h and protein extracted as
previously described for XPF–ERCC1. Following Strep-tactin afﬁnity puriﬁcation,
the complex was puriﬁed using anion-exchange (HiTrap-Q, GE Healthcare) using
a gradient of 150 mM NaCl to 500 mM NaCl over 20 ml of extract buffer minus
protease inhibitors and BaseMuncher. This separated the SLX4NTD–XPF–ERCC1
complex from unbound XPF–ERCC1. Fractions containing the
SLX4NTD–XPF–ERCC1 complex were pooled and concentrated prior to a ﬁnal
SEC step using a Superose-6 increase column equilibrated in extract buffer minus
protease inhibitors and BaseMuncher (GE Healthcare). Fractions containing both
XPF and SLX4NTD were identiﬁed via Western blot.
Real-time ﬂuorescence incision assay. Fluorescently labelled stem–loop (SLF)
DNA substrates, containing a 5′ 6-FAM ﬂuorophore and 3′-BHQ1 quench, were
puriﬁed by SEC (Superdex-200i, GE Healthcare) in assay buffer (5 mM HEPES,
10% glycerol, 0.5 mM DTT, 1 mM MnCl2 and 40 mM NaCl. The puriﬁed sub-
strates were then annealed by heating to 95 °C for 1 min followed by cooling to 4 °C
and dispensed into the assay plate. Reactions were carried out in 384-well black,
ﬂat-bottomed microtitre plates (Corning 3854). Puriﬁed XPF–ERCC1 was buffer
exchanged into assay buffer and 5 nM added to each in a total volume of 20 µl to
initiate the endonuclease reaction. Fluorescence measurements were carried out
using the CLARIOstar plate reader (BMG Labtech) using an excitation wavelength
of 483 nm and an emission wavelength of 525 nm. Sixty readings were collected at
30-s intervals and the linear response range for each substrate was used to deter-
mine the change in ﬂuorescence per unit time. Kinetic parameters were calculated
using the Michaelis–Menten equation. Experimental product release was quantiﬁed
by plotting the relative ﬂuorescence units produced by known amounts of the
cleavage products against their concentration to generate a standard curve.
SLF sequence: 6-FAM-5′-CAGCGCTUGGTTTTTTTTTTTTTTTTTTTTCCA
AGCGCTG-3′-BHQ1.
Cleavage product #1: 6-FAM-5′-CAGCGCTC 3′.
Cleavage product #2: 5′-GGTTTTTTTTTTTTTTTTTTTTCCGAGCGCTG-3′-
BHQ1.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The coordinates for the DNA-free and DNA-bound XPF–ERCC1 complex are available
in the PDB with codes 6SXA [https://www.ebi.ac.uk/pdbe/entry/pdb/6sxb] and 6SXB
[https://www.ebi.ac.uk/pdbe/entry/pdb/6sxb] and the cryo-EM maps are available in
EMDB with codes EMD-10337 [https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-10337]
and EMD-10338 [https://www.ebi.ac.uk/pdbe/entry/emdb/EMD-10337]. The source data
underlying Figs. 1b, 5b Supplementary Figs. 1b, 9d, e are provided as a Source Data ﬁle.
Other data that support the ﬁndings of this study are available from the corresponding
author upon request.
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